Key result
Culprit-only PCI plus Prolifiban achieves reperfusion and improves LVEF by 10% in a cardiogenic shock patient.
Why the study?
Multivessel acute total occlusion represents a rare, catastrophic form of MI often precipitating cardiogenic shock with exceptionally high mortality, presenting clinical complexity and therapeutic dilemmas.
Case Report (n=1)
Culprit-only PCI with adjunctive pharmacotherapy can successfully stabilize patients presenting with cardiogenic shock due to multivessel acute total occlusion.
Answers are grounded in this paper and cite their sources.
May support aggressive intervention in multivessel ATO; leaves open confirmation in larger randomized trials.
Multivessel acute total occlusion (ATO) represents an exceedingly rare and catastrophic form of acute myocardial infarction (MI), characterized by complete cessation of coronary flow in multiple epicardial vessels and profound ischemic burden. Such extensive coronary involvement often precipitates cardiogenic shock and carries exceptionally high mortality. This case report describes a 51-year-old male who presented with syncope and persistent chest pain following vigorous exertion. On admission, electrocardiography indicated acute anteroseptal and high lateral wall MI, and echocardiography revealed left ventricular dysfunction (LVEF 36%) with regional wall motion abnormalities. Coronary angiography demonstrated multivessel ATO involving proximal-mid left anterior descending (LAD) subtotal occlusion (TIMI 0-1), proximal left circumflex (LCx) total occlusion (TIMI 0), and mid right coronary artery (RCA) occlusion (TIMI 0). The patient developed cardiogenic shock requiring norepinephrine support. Guided by contemporary recommendations, culprit-only percutaneous coronary intervention (PCI) of the LCx was performed via right radial access, with intracoronary administration of a glycoprotein IIb/IIIa inhibitor (Prolifiban). A 2.75 × 23 mm drug-eluting stent was successfully implanted, achieving full reperfusion (TIMI 3) and rapid hemodynamic recovery. Subsequent staged LAD intervention was also successful. Post-procedural outcomes were favorable, with no recurrent syncope or chest pain and improved left ventricular ejection fraction to 46% at 30 days. This case highlights the clinical complexity and therapeutic dilemma of multivessel ATO presenting with syncope and cardiogenic shock. It underscores the importance of selective culprit-lesion revascularization, radial access, and adjunctive pharmacotherapy in achieving stabilization and favorable outcomes in this high-risk setting.
No takes yet. Share an insight, caveat, or question.
Aimaierjiang et al. (2026) conducted a case report in Multivessel acute total occlusion with cardiogenic shock (n=1). Culprit-only percutaneous coronary intervention (PCI) with intracoronary Prolifiban was evaluated on Reperfusion and left ventricular ejection fraction. Culprit-only PCI with intracoronary Prolifiban in a patient with multivessel acute total occlusion and cardiogenic shock achieved full reperfusion and improved LVEF from 36% to 46% at 30 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: